Clinical radiology · 2026
Distinguishing focal nodular hyperplasia from hepatocellular adenoma on contrast-enhanced ultrasound: a systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen L, Altmayer S, Tse J R
Аннотация
AIM: Single-centre studies with modest sized samples have shown that contrast-enhanced ultrasound (CEUS) can distinguish focal nodular hyperplasia (FNH) from hepatocellular adenomas (HCAs). We performed a systematic review and meta-analysis to evaluate the diagnostic performance of CEUS in distinguishing FNH from HCA.
MATERIALS AND METHODS: PubMed, Embase, and Web of Science were searched up to January 2026 for studies that evaluated FNHs and HCAs using CEUS, with histopathology or magnetic resonance imaging (MRI) with hepatobiliary contrast agent as the reference standard. The diagnostic performance of CEUS from individual studies was extracted. Pooled sensitivity and specificity with 95% confidence interval (CI) were obtained using a bivariate random-effects model. A summary receiver-operating characteristic curve (SROC) was generated to estimate the area under the curve (AUC) via parametric bootstrapping.
RESULTS: Five scientific studies were included, with a total of 228 FNHs and 155 HCAs. Final diagnoses were established by histology alone in one study and by MRI with hepatobiliary contrast in four studies. Three of the five studies were at overall low risk of bias, with concerns mainly related to patient selection. The pooled sensitivity and specificity of CEUS to differentiate FNH from HCA were 84.9% (95% CI, 69.8-93.2%) and 84.1% (95% CI, 74.8-90.4%), respectively. The AUC was 0.90 (95% CI, 0.80-0.93).
CONCLUSION: CEUS showed promising diagnostic performance for distinguishing FNH from HCA. However, given the small number of studies and the predominant use of MRI with hepatobiliary contrast rather than histology as the reference standard, these findings should be considered exploratory.
MATERIALS AND METHODS: PubMed, Embase, and Web of Science were searched up to January 2026 for studies that evaluated FNHs and HCAs using CEUS, with histopathology or magnetic resonance imaging (MRI) with hepatobiliary contrast agent as the reference standard. The diagnostic performance of CEUS from individual studies was extracted. Pooled sensitivity and specificity with 95% confidence interval (CI) were obtained using a bivariate random-effects model. A summary receiver-operating characteristic curve (SROC) was generated to estimate the area under the curve (AUC) via parametric bootstrapping.
RESULTS: Five scientific studies were included, with a total of 228 FNHs and 155 HCAs. Final diagnoses were established by histology alone in one study and by MRI with hepatobiliary contrast in four studies. Three of the five studies were at overall low risk of bias, with concerns mainly related to patient selection. The pooled sensitivity and specificity of CEUS to differentiate FNH from HCA were 84.9% (95% CI, 69.8-93.2%) and 84.1% (95% CI, 74.8-90.4%), respectively. The AUC was 0.90 (95% CI, 0.80-0.93).
CONCLUSION: CEUS showed promising diagnostic performance for distinguishing FNH from HCA. However, given the small number of studies and the predominant use of MRI with hepatobiliary contrast rather than histology as the reference standard, these findings should be considered exploratory.